Hospital & Healthcare Services · Founded 2002 · www.jupiterhospital.com · BSE 543980 · NSE JLHL · ISIN INE682M01012
No Notes Added Yet
Business
Jupiter Life Line Hospitals Ltd. is a multi-specialty tertiary and quaternary healthcare provider operating in the Western India region. The company primarily offers comprehensive medical services across various disciplines, including but not limited to cardiac sciences, neurosciences, oncology, orthopedics, gastroenterology, and pediatrics. Its core business model involves operating and managing hospitals with a focus on delivering quality patient care through a combination of inpatient, outpatient, and emergency services. The company generates revenue through patient billings for medical consultations, diagnostic tests, surgical procedures, room charges, and pharmacy sales.
Revenue Mix
Jupiter Life Line Hospitals operates through its chain of multi-specialty hospitals. While specific numerical breakdowns are not consistently disclosed for all service lines, the company's revenue primarily stems from:
Inpatient Services: This constitutes the majority of revenue, derived from patient admissions for surgeries, complex medical treatments, and long-term care across various specialties.
Outpatient Services: Revenue from consultations, diagnostic imaging, pathology tests, and minor procedures performed in outpatient departments.
Emergency & Critical Care: Services provided in emergency rooms and intensive care units.
Pharmacy & Other Ancillary Services: Income from in-house pharmacies and other support services.
Its hospitals in Thane, Pune, and Indore cater to a broad range of specialties, with strong contributions from areas like cardiac sciences, neurosciences, and orthopedics.
Industry
The Indian hospital and healthcare services industry is characterized by strong growth, driven by increasing disposable incomes, rising health awareness, higher penetration of health insurance, and a growing burden of lifestyle diseases. It is a mix of public and private players, with private corporate hospital chains like Jupiter playing a significant role in tertiary and quaternary care. Jupiter Life Line Hospitals is positioned as a regional leader in Western India, particularly in its primary markets of Thane and Pune, offering high-end multi-specialty care. It competes with other established large corporate hospital chains (e.g., Apollo, Fortis, Max Healthcare in certain geographies) and smaller regional hospital groups, differentiating itself through its strong clinical teams, infrastructure, and patient outcomes in its target areas.
MOAT
Jupiter Life Line Hospitals possesses several competitive advantages:
Regional Brand & Reputation: Established brand name and strong clinical reputation in its key operational geographies (Thane, Pune, Indore), leading to patient trust and preference.
Specialized Infrastructure & Clinical Talent: Investment in advanced medical technology and a strong roster of experienced medical professionals and specialists, enabling it to handle complex tertiary and quaternary cases.
Location Advantage: Strategic locations of its hospitals in densely populated and growing urban centers, ensuring high patient footfall and accessibility.
Operational Efficiency: Demonstrated ability to achieve high bed occupancy rates and manage operations effectively within its existing facilities.
Growth Drivers
Key factors that can drive growth for Jupiter Life Line Hospitals over the next 3-5 years include:
Expansion of Network: Commissioning of new hospitals (e.g., Palghar) and potential bed capacity expansion in existing facilities.
Increasing Healthcare Expenditure: Continued rise in private healthcare spending and health insurance penetration in India.
Medical Tourism: Potential to attract patients from neighboring regions and internationally due to quality healthcare at competitive costs.
Demographic Shifts: Aging population and increasing prevalence of lifestyle diseases driving demand for specialized medical services.
Focus on High-Yield Specialties: Continued emphasis on complex procedures and critical care, which typically command higher revenue per patient.
Risks
Intense Competition: The Indian healthcare market is competitive, with established national chains and new entrants vying for market share, potentially leading to pricing pressures.
Regulatory Changes: Government interventions such as price capping on medical procedures or devices, changes in insurance reimbursement policies, or new licensing requirements could impact profitability.
Talent Retention: Dependence on highly skilled doctors, nurses, and medical staff. Attrition of key personnel could affect service quality and reputation.
High Capital Expenditure: Hospital expansion and technology upgrades require substantial capital investment, posing financial risks if not managed efficiently or if occupancy rates fall short.
Medical Malpractice & Litigation: Risks associated with medical errors or adverse patient outcomes can lead to legal liabilities and reputational damage.
Management & Ownership
The company is promoted by Dr. Ajay Sharma, who also serves as the Managing Director and is a key figure in its clinical and strategic direction. He has significant experience in the healthcare sector. The management team comprises experienced professionals in clinical operations, finance, and administration. The promoter group holds a significant stake in the company, aligning their interests with long-term growth. Post-IPO, there is a mix of promoter holding, institutional investors, and public shareholders, with institutional backing providing governance oversight.
Outlook
Jupiter Life Line Hospitals is well-positioned within the growing Indian healthcare market, benefiting from increasing demand for multi-specialty care and its strong regional presence. Its strategic expansion plans and focus on high-acuity services present avenues for sustained revenue and profit growth. However, the company operates in a capital-intensive and highly regulated industry. Key challenges include managing intense competition, navigating potential regulatory changes that could impact pricing, and effectively attracting and retaining top medical talent. Its ability to successfully execute expansion projects while maintaining operational efficiencies and quality patient outcomes will be crucial for its future performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 273 | 291 | 289 | 335 | 333 | 337 | 348 | 394 | 365 | 388 |
| Other Income | 8 | 8 | 7 | 7 | 7 | 7 | 13 | 11 | 9 | 9 |
| Total Income | 281 | 299 | 295 | 342 | 340 | 344 | 360 | 405 | 374 | 397 |
| Total Expenditure | 211 | 228 | 223 | 257 | 256 | 257 | 270 | 301 | 282 | 299 |
| Operating Profit | 70 | 71 | 72 | 86 | 84 | 87 | 91 | 104 | 93 | 98 |
| Interest | 1 | 1 | 1 | 1 | 3 | 6 | 8 | 8 | 8 | 9 |
| Depreciation | 11 | 10 | 11 | 14 | 14 | 18 | 21 | 21 | 22 | 23 |
| Exceptional Income / Expenses | -0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | -6 | 2 |
| Profit Before Tax | 58 | 62 | 60 | 70 | 67 | 63 | 62 | 74 | 57 | 68 |
| Provision for Tax | 14 | 17 | 16 | 18 | 15 | 18 | 18 | 17 | 14 | 17 |
| Profit After Tax | 44 | 45 | 45 | 52 | 52 | 45 | 44 | 57 | 42 | 50 |
| Adjustments | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 |
| Profit After Adjustments | 44 | 45 | 44 | 52 | 52 | 45 | 44 | 57 | 43 | 50 |
| Adjusted Earnings Per Share | 6.7 | 6.9 | 6.8 | 7.9 | 7.9 | 6.9 | 6.7 | 8.7 | 6.5 | 7.7 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 463 | 486 | 733 | 893 | 1073 | 1262 | 1495 |
| Other Income | 2 | 4 | 4 | 10 | 22 | 29 | 42 |
| Total Income | 465 | 490 | 737 | 903 | 1095 | 1290 | 1536 |
| Total Expenditure | 380 | 419 | 580 | 691 | 831 | 965 | 1152 |
| Operating Profit | 84 | 71 | 157 | 212 | 264 | 325 | 386 |
| Interest | 26 | 39 | 44 | 42 | 26 | 11 | 33 |
| Depreciation | 26 | 31 | 36 | 39 | 42 | 57 | 87 |
| Exceptional Income / Expenses | 0 | 0 | -0 | -2 | 0 | 0 | -4 |
| Profit Before Tax | 33 | 2 | 77 | 129 | 195 | 258 | 261 |
| Provision for Tax | 3 | 4 | 26 | 56 | 19 | 64 | 66 |
| Profit After Tax | 30 | -2 | 51 | 73 | 177 | 194 | 193 |
| Adjustments | 0 | 0 | 0 | 0 | 1 | -1 | 0 |
| Profit After Adjustments | 30 | -2 | 51 | 73 | 178 | 192 | 194 |
| Adjusted Earnings Per Share | 5.8 | -0.5 | 10.1 | 12.9 | 27.1 | 29.3 | 29.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 18% | 20% | 22% | 0% |
| Operating Profit CAGR | 23% | 27% | 31% | 0% |
| PAT CAGR | 10% | 56% | 45% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -10% | NA% | NA% | NA% |
| ROE Average | 15% | 20% | 16% | 15% |
| ROCE Average | 19% | 21% | 17% | 16% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 237 | 239 | 294 | 366 | 1169 | 1356 |
| Minority's Interest | 0 | 7 | -5 | -2 | -0 | 0 |
| Borrowings | 244 | 421 | 465 | 453 | 0 | 322 |
| Other Non-Current Liabilities | 20 | 25 | 33 | 37 | 7 | 74 |
| Total Current Liabilities | 103 | 96 | 123 | 132 | 106 | 152 |
| Total Liabilities | 603 | 789 | 909 | 986 | 1281 | 1905 |
| Fixed Assets | 435 | 630 | 684 | 720 | 718 | 977 |
| Other Non-Current Assets | 35 | 46 | 44 | 57 | 154 | 240 |
| Total Current Assets | 134 | 113 | 180 | 209 | 410 | 687 |
| Total Assets | 603 | 789 | 909 | 986 | 1281 | 1905 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 8 | 7 | 18 | 103 | 26 | 23 |
| Cash Flow from Operating Activities | 74 | 123 | 137 | 117 | 115 | 253 |
| Cash Flow from Investing Activities | -43 | -296 | -85 | -104 | -246 | -209 |
| Cash Flow from Financing Activities | -32 | 185 | 33 | 18 | 128 | 301 |
| Net Cash Inflow / Outflow | -1 | 12 | 85 | 31 | -3 | 345 |
| Closing Cash & Cash Equivalent | 7 | 19 | 103 | 134 | 23 | 368 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.83 | -0.45 | 10.05 | 12.9 | 27.13 | 29.33 |
| CEPS(Rs) | 10.92 | 5.59 | 17.16 | 19.72 | 33.4 | 38.2 |
| DPS(Rs) | 0 | 0 | 1 | 1 | 1 | 1 |
| Book NAV/Share(Rs) | 46.54 | 46.98 | 57.36 | 64.7 | 178.3 | 206.85 |
| Core EBITDA Margin(%) | 17.84 | 13.81 | 20.92 | 22.56 | 22.55 | 23.51 |
| EBIT Margin(%) | 12.65 | 8.34 | 16.51 | 19.16 | 20.66 | 21.26 |
| Pre Tax Margin(%) | 7.1 | 0.32 | 10.52 | 14.42 | 18.2 | 20.43 |
| PAT Margin (%) | 6.4 | -0.47 | 6.97 | 8.17 | 16.45 | 15.34 |
| Cash Profit Margin (%) | 12 | 5.85 | 11.91 | 12.49 | 20.4 | 19.86 |
| ROA(%) | 4.91 | -0.33 | 6.02 | 7.7 | 15.58 | 12.15 |
| ROE(%) | 12.52 | -0.97 | 19.27 | 22.18 | 23.02 | 15.33 |
| ROCE(%) | 11.52 | 6.91 | 16.66 | 21.07 | 22.14 | 18.82 |
| Receivable days | 35.17 | 24.95 | 12.37 | 15.04 | 17.49 | 14.34 |
| Inventory Days | 11.01 | 10.14 | 7.07 | 7.02 | 6.86 | 6.57 |
| Payable days | 267.8 | 217.2 | 153.57 | 153.08 | 128.08 | 130.95 |
| PER(x) | 0 | 0 | 0 | 0 | 44.16 | 54.32 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 6.72 | 7.7 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0.08 | 0.06 |
| EV/Net Sales(x) | 0.68 | 0.94 | 0.6 | 0.44 | 7.04 | 8.15 |
| EV/Core EBITDA(x) | 3.74 | 6.41 | 2.81 | 1.85 | 28.59 | 31.62 |
| Net Sales Growth(%) | 0 | 5.02 | 50.8 | 21.75 | 20.27 | 17.52 |
| EBIT Growth(%) | 0 | -30.81 | 198.67 | 41.24 | 29.7 | 20.97 |
| PAT Growth(%) | 0 | -107.75 | 2325.86 | 42.59 | 142.25 | 9.56 |
| EPS Growth(%) | 0 | -107.75 | 2325.71 | 28.34 | 110.29 | 8.14 |
| Debt/Equity(x) | 1.15 | 1.78 | 1.7 | 1.28 | 0 | 0.24 |
| Current Ratio(x) | 1.3 | 1.18 | 1.46 | 1.58 | 3.87 | 4.51 |
| Quick Ratio(x) | 1.16 | 1.04 | 1.34 | 1.44 | 3.67 | 4.35 |
| Interest Cover(x) | 2.28 | 1.04 | 2.76 | 4.04 | 8.42 | 25.42 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0.03 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 |
| FII | 3.97 | 4.17 | 6.06 | 8.84 | 10.04 | 10.03 | 9.77 | 9.06 | 8.48 | 8.48 |
| DII | 13.93 | 14.16 | 13.85 | 13.46 | 12.33 | 12.22 | 12.41 | 13.54 | 14.02 | 13.6 |
| Public | 41.19 | 40.75 | 39.17 | 36.79 | 36.72 | 36.84 | 36.91 | 36.49 | 36.59 | 37.01 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 |
| FII | 0.26 | 0.27 | 0.4 | 0.58 | 0.66 | 0.66 | 0.64 | 0.59 | 0.56 | 0.56 |
| DII | 0.91 | 0.93 | 0.91 | 0.88 | 0.81 | 0.8 | 0.81 | 0.89 | 0.92 | 0.89 |
| Public | 2.7 | 2.67 | 2.57 | 2.41 | 2.41 | 2.42 | 2.42 | 2.39 | 2.4 | 2.43 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +18% | +20% | +22% | — |
| Operating Profit CAGR | +23% | +27% | +31% | — |
| PAT CAGR | +10% | +56% | +45% | — |
| Share Price CAGR | -10% | — | — | — |
| ROE Average | +15% | +20% | +16% | +15% |
| ROCE Average | +19% | +21% | +17% | +16% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 |
| FII | 3.97 | 4.17 | 6.06 | 8.84 | 10.04 | 10.03 | 9.77 | 9.06 | 8.48 | 8.48 |
| DII | 13.93 | 14.16 | 13.85 | 13.46 | 12.33 | 12.22 | 12.41 | 13.54 | 14.02 | 13.6 |
| Public | 59.09 | 59.09 | 59.09 | 59.09 | 59.09 | 59.09 | 59.09 | 59.09 | 59.09 | 59.09 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 |
| FII | 0.26 | 0.27 | 0.4 | 0.58 | 0.66 | 0.66 | 0.64 | 0.59 | 0.56 | 0.56 |
| DII | 0.91 | 0.93 | 0.91 | 0.88 | 0.81 | 0.8 | 0.81 | 0.89 | 0.92 | 0.89 |
| Public | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.